header logo image


Page 1,314«..1020..1,3131,3141,3151,316..1,3201,330..»

Initiating Regeneration with Stem Cells | Tomorrow Today – Interview – Video

April 19th, 2013 8:45 pm


Initiating Regeneration with Stem Cells | Tomorrow Today - Interview
Professor Georg Duda from the Julius Wolf Institut of the Charite, talks about the biomechanics of the spine and its regeneration. Why are deep muscles so im...

By: deutschewelleenglish

Original post:
Initiating Regeneration with Stem Cells | Tomorrow Today - Interview - Video

Read More...

The surprising ability of blood stem cells to respond to emergencies – Video

April 19th, 2013 8:45 pm


The surprising ability of blood stem cells to respond to emergencies
A research team of Inserm, CNRS and MDC lead by Michael Sieweke of the Centre d #39;Immunologie de Marseille Luminy (CNRS, INSERM, Aix Marseille Université) and ...

By: InsermDisc

Follow this link:
The surprising ability of blood stem cells to respond to emergencies - Video

Read More...

Where can mesenchymal stem cells be found? – Video

April 19th, 2013 8:45 pm


Where can mesenchymal stem cells be found?
http://www.stemcellsarthritistreatment.com Sometimes trying to find stem cells to use for arthritis treatment is like a sophisticated version of Where #39;s Walso? Here #39;s why... Tuan and colleagues...

By: Nathan Wei

Read the original:
Where can mesenchymal stem cells be found? - Video

Read More...

FDA approves Phase II clinical trial of stem cells for Lou Gehrig’s disease (ALS) – Video

April 19th, 2013 8:45 pm


FDA approves Phase II clinical trial of stem cells for Lou Gehrig #39;s disease (ALS)
Dr. Eva Feldman, U-M neurologist and director of the A. Alfred Taubman Medical Research Institute, discusses the recent FDA approval of a new phase for a cli...

By: UMHealthSystem

More here:
FDA approves Phase II clinical trial of stem cells for Lou Gehrig's disease (ALS) - Video

Read More...

Help Jayden’s Fight for a Cure! Learn About Donating Bone Marrow/Stem cells. Donors Fight Leukemia – Video

April 15th, 2013 1:44 pm


Help Jayden #39;s Fight for a Cure! Learn About Donating Bone Marrow/Stem cells. Donors Fight Leukemia
In this video I introduce you to Jayden ( http://www.facebook.com/cureforjayden ) who is a brave four year old girl who loves all things princess. But Jayden...

By: Bradford Pine

Here is the original post:
Help Jayden's Fight for a Cure! Learn About Donating Bone Marrow/Stem cells. Donors Fight Leukemia - Video

Read More...

Tam Dalyell Prize lecture – Stem Cells: A Vision of the Future – Video

April 15th, 2013 1:44 pm


Tam Dalyell Prize lecture - Stem Cells: A Vision of the Future
Professor Clare Blackburn and Dr Amy Hardie deliver a presentation exploring the history, biology, hopes and fears of stem cell research, the product of an i...

By: EdinburghUniversity

Read the original:
Tam Dalyell Prize lecture - Stem Cells: A Vision of the Future - Video

Read More...

Vatican hosts conference on advancements in stem cell therapy – Video

April 14th, 2013 3:46 am


Vatican hosts conference on advancements in stem cell therapy
http://en.romereports.com.

By: romereports

Read the original here:
Vatican hosts conference on advancements in stem cell therapy - Video

Read More...

The Mystery about Cyanide Taste

April 14th, 2013 3:15 am

What is potassium cyanide??

A chemical compound with the chemical formula KCN is commonly known as the Potassium cyanide. This is a colorless crystalline compound, highly soluble in water and is similar in appearance as that of sugar. Potassium cyanide is considered to be highly toxic in nature. Potassium cyanide is considered to be one of the most deadly compounds being discovered till date.

Production of Potassium Cyanide:

Potassium Cyanide can be produced mainly by treating hydrogen cyanide in the presence of a fifty percent of an aqueous solution of potassium hydroxide. After that the aqueous solution is either evaporated in a vacuum or by treating the form amide in the presence of potassium hydroxide. On an average per year approximately fifty thousand tons of potassium cyanide are being produced all over the world.

Use of Potassium Cyanide:

Potassium Cyanide is mainly used for the purpose of electroplating, organic synthesis of a number of chemical compounds, gold mining and so on. In accordance with the large scale use of Potassium Cyanide, it is also used in smaller scale applications like in the jewelry manufacturing industry for chemical buffing and gliding. Other than those mentioned earlier, Potassium Cyanide is also used by the entomologists as it is an excellent killing agent, and it has the unique capability of causing minimum damage to the highly fragile specimens.

Mystery about Potassium Cyanide:

Since, the time of its invention, the biggest mystery that has been surrounded with Potassium Cyanide, is about the taste of it. Due to the fact that Potassium Cyanide is exceedingly poisonous substance and can cause death of a person in seconds, the taste of it has remained a mystery or a fact yet to be known to the world. Though, many researches and tests have been conducted to find the taste of Potassium Cyanide but none of them could come up with the appropriate result.

Different views about the taste of Potassium Cyanide:

There has been number of views among the scientists about the taste of the Potassium Cyanide, some of them are as follows:

· Since on hydrolysis of KCN, the resultant compound that are formed are KOH and HCN, which are strong base and weak base respectively, Potassium Cyanide is confirmed to be basic nature. Since at room temperature HCN is a gas which evolves and the solution is expected to have more KOH, so the taste of Potassium Cyanide is assumed to be bitter.

· Some, scientists who have died while finding the taste of Potassium cyanide, could only write the alphabet “S” before dying, so it is not conclusive whether it is sour, sweet or salty in taste.

Conclusion:

Though, a huge number of scientists sacrificed their lives in order to find the taste of Potassium cyanide, but it remained a mystery for long, until and unless a goldsmith from India named MP Prasad in an attempt to commit suicide with the help of Potassium cyanide could finally reveal the taste of Potassium cyanide. As per the suicide note of him the taste of Potassium Cyanide is very much acrid, that is irritatingly harsh and sharp. This fact about the taste of Potassium cyanide is approved by the World Health Organization and is marked as an extraordinary discovery in the field of science.

Source:
http://www.biotechblog.org/entry/mystery-cyanide-taste/

Read More...

StemCells, Inc., Nails Down Controversial, $19 Million Award from California Stem Cell Agency

April 14th, 2013 3:14 am

The stock price of StemCells, Inc.,
price today jumped as much as 9 percent after the company disclosed
it had finally concluded an agreement with the California stem cell
agency for a $19.3 million forgivable loan for research twice rejected by the agency's scientific reviewers..

The stem cell agency governing board seven months ago approved the loan to the Newark, Ca., firm. But the
cash was withheld until the financially strapped company could
demonstrate that it could match the size of the loan, as promised in
its application.
The StemCells, Inc., (SCI) application
was nixed two times in 2012 by the agency's scientific reviewers who gave it a
score of 61. In a controversial move, the 29-member board approved the award in early September on a 7-5 vote after former agency
chairman Robert Klein intervened publicly on behalf of the firm. It was the first time that Klein had lobbied the board publicly on behalf of an application. It was also the first time that the board
approved an application that was rejected twice by its reviewers, a
panel of internationally recognized stem cell scientists.
In a press release, Martin McGlynn,
CEO of StemCells, Inc., said,

"With CIRM's support, we are now
able to lay the groundwork that could result in the world's first
neural stem cell trial in Alzheimer's patients."

Both the company and the $3 billion
state research agency were tight-lipped about the nature of the
matching funds from the company, which reported losses of $28.5
million in 2012 on revenues of $1.4 million.
In a brief response to questions from the
California Stem Cell Report, McGlynn said, 

 “At this time, we
do not intend to elaborate any further on the contents of our press
releases or public filings pertaining to the SVB (Silicon Valley Bank) or CIRM(the stem cell agency) loans.”

Earlier this week, the company reported receiving a $10 million loan from Silicon Valley Bank. Both McGlynn
and the stem cell agency did not answer a question about whether
those funds are being used to back the award from California
taxpayers.
The agency confirmed that the firm was
providing $19.3 million in matching resources. But Kevin McCormack,
senior director of public communications, did not provide any
specifics on the nature of the match. He only said,

“The matching  requires
them to demonstrate they have enough funds necessary to
fund SCI’s share going forward as well as their own
operations and other commitments.”

The award was originally for $20
million. We have queried the agency about the smaller figure
announced today.
The company's stock price rose as high as $1.87 earlier today after closing at $1.71 yesterday. It stood at
$1.77 at the time of this writing. Its 52 week high is $2.67, and its
52 week low is $0.59. The loan from Silicon Valley Bank gives the
bank warrants to purchase 293,531 shares of the company at $1.70 over
the next 10 years.
The 10-year loan from CIRM is low risk for the
company, which said its “obligation to repay the loan will be
contingent upon the success” of the research. If a product is
developed, it will take years before it could hit the market.
The award to StemCells, Inc., put
the stem cell agency in a touchy situation involving the company's decision last month to reject an additional $20 million award from
the agency.( It was the first time a recipient has rejected an award.) Neither the company nor the agency would give a reason for
the rejection of the loan for a spinal injury project . However, the
award also required a $20 million match, which undoubtedly tested the company's resources.
The spinal injury application was
scored at 79 by agency reviewers and was routinely approved by the
board. With its withdrawal by the company, the agency, which prides
itself on funding only the best science, was left supporting research
(StemCells, Inc.'s Alzheimer's project) judged significantly inferior
by reviewers with its score of 61.
In response to a question about that
situation, CIRM's McCormack said,

“Our goal is to always fund the best,
most promising science. This is not the first time that our board has
voted to fund a project that the Grants Review Group had not
recommended (this has happened in around 2% of cases) The board did
so for a number of reasons, not the least of which is that this was
the first disease team application that had a goal of  moving a
promising stem cell therapy for Alzheimer's towards clinical
trials.”

The round in question, however, had another application dealing with Alzheimer's which was scored at 63,
two points higher than the one from StemCells, Inc. Reviewers also did not recommend funding that application.
The action last September by the
agency board came only after it publicly said the funds would not be
distributed until the StemCells, Inc., could show it could provide
the match, still another first for the agency.
The award triggered a column in
the Los Angeles Times by Pulitzer Prize winning writer Michael
Hiltzik
, who said in October that  the
process was “redolent of cronyism.”
 He said a “charmed
relationship” existed among StemCells, Inc., its “powerful
friends” and the stem cell agency.
StemCells, Inc., was founded by
Stanford researcher Irv Weissman, who was a major fundraiser for
Proposition 71, which created the stem cell agency in 2004. Klein
headed the ballot campaign, which spent more than $30 million to win
voter approval. Weissman sits on board of directors of StemCells,
Inc., and holds 124,608 shares in the firm, including 8,630 he reported this month receiving.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/34J6wy7wpLY/stemcells-inc-nails-down-controversial.html

Read More...

Modest Approval from Long-time Stem Cell Agency Critic

April 14th, 2013 3:14 am

Of all California's newspapers, The
Sacramento Bee
, the only daily paper in the state capital, has long
been the most critical – editorially – of the Golden State's $3
billion stem cell research agency.

Today, however, the newspaper gave a
modest nod of approval to the agency's modest efforts to clean up its
built-in conflicts of interest, which have been cited as a major flaw
by the prestigious Institute of Medicine.
The headline on the Bee's editorial today said,

“Stem cell agency finally addresses
potential for conflicts”

The piece said that Jonathan Thomas,
chairman of the agency, “has taken important steps in
reducing the potential for conflicts within this agency.”
The editorial continued,

 “He hasn't
gone as far as we would like, or that independent outside reviewers
have recommended....But he's achieved what's possible, at least for
now, and the board may empower him to go further.”

The Bee referred to action last month
in which the agency's governing board decided, among other things,
that 13 of the 15 board members linked to recipient institutions
could not vote on any grants, although they could participate in
discussion of applications. Twenty-nine persons sit on the board. In
a $700,000 report commissioned by the agency, the Institute of
Medicine recommended a fully independent board.
The Sacramento newspaper said, 

“We
think Thomas and the oversight board should go further and adopt the
Institute of Medicine recommendations. But that is politically
unlikely. As is now obvious, it will be up to the Legislature to
fully remove representatives of funding-eligible institutions from
being involved in decisions about grants that could come back to
them.

“Thomas, to his credit, recognizes
that his compromise may not be the perfect solution. He wants to test
out the new policy for a year, and see how it works. There's a lot
riding on the outcome. CIRM is expected to run out of funds in 2017,
and while philanthropy and foundation money could extend that for a
few years, supporters of California stem cell research clearly want
to go back to the ballot to seek additional funding. To make that
case, CIRM supporters can't afford any more scandals about insider
dealing. The next year will reveal whether it is on the right track.”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/NowG2d8N5CM/modest-approval-from-long-time-stem.html

Read More...

StemCells, Inc., Nails Down Controversial, $19 Million Award from California Stem Cell Agency

April 14th, 2013 3:10 am

The stock price of StemCells, Inc.,
price today jumped as much as 9 percent after the company disclosed
it had finally concluded an agreement with the California stem cell
agency for a $19.3 million forgivable loan for research twice rejected by the agency's scientific reviewers..

The stem cell agency governing board seven months ago approved the loan to the Newark, Ca., firm. But the
cash was withheld until the financially strapped company could
demonstrate that it could match the size of the loan, as promised in
its application.
The StemCells, Inc., (SCI) application
was nixed two times in 2012 by the agency's scientific reviewers who gave it a
score of 61. In a controversial move, the 29-member board approved the award in early September on a 7-5 vote after former agency
chairman Robert Klein intervened publicly on behalf of the firm. It was the first time that Klein had lobbied the board publicly on behalf of an application. It was also the first time that the board
approved an application that was rejected twice by its reviewers, a
panel of internationally recognized stem cell scientists.
In a press release, Martin McGlynn,
CEO of StemCells, Inc., said,

"With CIRM's support, we are now
able to lay the groundwork that could result in the world's first
neural stem cell trial in Alzheimer's patients."

Both the company and the $3 billion
state research agency were tight-lipped about the nature of the
matching funds from the company, which reported losses of $28.5
million in 2012 on revenues of $1.4 million.
In a brief response to questions from the
California Stem Cell Report, McGlynn said, 

 “At this time, we
do not intend to elaborate any further on the contents of our press
releases or public filings pertaining to the SVB (Silicon Valley Bank) or CIRM(the stem cell agency) loans.”

Earlier this week, the company reported receiving a $10 million loan from Silicon Valley Bank. Both McGlynn
and the stem cell agency did not answer a question about whether
those funds are being used to back the award from California
taxpayers.
The agency confirmed that the firm was
providing $19.3 million in matching resources. But Kevin McCormack,
senior director of public communications, did not provide any
specifics on the nature of the match. He only said,

“The matching  requires
them to demonstrate they have enough funds necessary to
fund SCI’s share going forward as well as their own
operations and other commitments.”

The award was originally for $20
million. We have queried the agency about the smaller figure
announced today.
The company's stock price rose as high as $1.87 earlier today after closing at $1.71 yesterday. It stood at
$1.77 at the time of this writing. Its 52 week high is $2.67, and its
52 week low is $0.59. The loan from Silicon Valley Bank gives the
bank warrants to purchase 293,531 shares of the company at $1.70 over
the next 10 years.
The 10-year loan from CIRM is low risk for the
company, which said its “obligation to repay the loan will be
contingent upon the success” of the research. If a product is
developed, it will take years before it could hit the market.
The award to StemCells, Inc., put
the stem cell agency in a touchy situation involving the company's decision last month to reject an additional $20 million award from
the agency.( It was the first time a recipient has rejected an award.) Neither the company nor the agency would give a reason for
the rejection of the loan for a spinal injury project . However, the
award also required a $20 million match, which undoubtedly tested the company's resources.
The spinal injury application was
scored at 79 by agency reviewers and was routinely approved by the
board. With its withdrawal by the company, the agency, which prides
itself on funding only the best science, was left supporting research
(StemCells, Inc.'s Alzheimer's project) judged significantly inferior
by reviewers with its score of 61.
In response to a question about that
situation, CIRM's McCormack said,

“Our goal is to always fund the best,
most promising science. This is not the first time that our board has
voted to fund a project that the Grants Review Group had not
recommended (this has happened in around 2% of cases) The board did
so for a number of reasons, not the least of which is that this was
the first disease team application that had a goal of  moving a
promising stem cell therapy for Alzheimer's towards clinical
trials.”

The round in question, however, had another application dealing with Alzheimer's which was scored at 63,
two points higher than the one from StemCells, Inc. Reviewers also did not recommend funding that application.
The action last September by the
agency board came only after it publicly said the funds would not be
distributed until the StemCells, Inc., could show it could provide
the match, still another first for the agency.
The award triggered a column in
the Los Angeles Times by Pulitzer Prize winning writer Michael
Hiltzik
, who said in October that  the
process was “redolent of cronyism.”
 He said a “charmed
relationship” existed among StemCells, Inc., its “powerful
friends” and the stem cell agency.
StemCells, Inc., was founded by
Stanford researcher Irv Weissman, who was a major fundraiser for
Proposition 71, which created the stem cell agency in 2004. Klein
headed the ballot campaign, which spent more than $30 million to win
voter approval. Weissman sits on board of directors of StemCells,
Inc., and holds 124,608 shares in the firm, including 8,630 he reported this month receiving.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/34J6wy7wpLY/stemcells-inc-nails-down-controversial.html

Read More...

Modest Approval from Long-time Stem Cell Agency Critic

April 14th, 2013 3:10 am

Of all California's newspapers, The
Sacramento Bee
, the only daily paper in the state capital, has long
been the most critical – editorially – of the Golden State's $3
billion stem cell research agency.

Today, however, the newspaper gave a
modest nod of approval to the agency's modest efforts to clean up its
built-in conflicts of interest, which have been cited as a major flaw
by the prestigious Institute of Medicine.
The headline on the Bee's editorial today said,

“Stem cell agency finally addresses
potential for conflicts”

The piece said that Jonathan Thomas,
chairman of the agency, “has taken important steps in
reducing the potential for conflicts within this agency.”
The editorial continued,

 “He hasn't
gone as far as we would like, or that independent outside reviewers
have recommended....But he's achieved what's possible, at least for
now, and the board may empower him to go further.”

The Bee referred to action last month
in which the agency's governing board decided, among other things,
that 13 of the 15 board members linked to recipient institutions
could not vote on any grants, although they could participate in
discussion of applications. Twenty-nine persons sit on the board. In
a $700,000 report commissioned by the agency, the Institute of
Medicine recommended a fully independent board.
The Sacramento newspaper said, 

“We
think Thomas and the oversight board should go further and adopt the
Institute of Medicine recommendations. But that is politically
unlikely. As is now obvious, it will be up to the Legislature to
fully remove representatives of funding-eligible institutions from
being involved in decisions about grants that could come back to
them.

“Thomas, to his credit, recognizes
that his compromise may not be the perfect solution. He wants to test
out the new policy for a year, and see how it works. There's a lot
riding on the outcome. CIRM is expected to run out of funds in 2017,
and while philanthropy and foundation money could extend that for a
few years, supporters of California stem cell research clearly want
to go back to the ballot to seek additional funding. To make that
case, CIRM supporters can't afford any more scandals about insider
dealing. The next year will reveal whether it is on the right track.”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/NowG2d8N5CM/modest-approval-from-long-time-stem.html

Read More...

Chicago Arthritis – What is Regenerative Medicine – Video

April 12th, 2013 4:44 pm


Chicago Arthritis - What is Regenerative Medicine
Dr Tambar at Chicago Arthritis discusses regenerative medicine techniques, prp and stem cells, for arthritis and tendinitis.

By: ChicagoArthritis

Link:
Chicago Arthritis - What is Regenerative Medicine - Video

Read More...

Vatican Conference Hopes to Promote Truth on Adult Stem Cell Therapy

April 12th, 2013 5:42 am

Doctors, Patients Speak on Personal Experiences Vatican City, April 11, 2013 (Zenit.org) Junno Arocho Esteves | 488 hits

During todays first session of the Second International Vatican Adult Stem Cell Conference, scientists, doctors and patients had an opportunity to share not only the advances in adult stem cell research, but also the potential it has to transform modern day health care.

The ethical debate on the use of embryonic stem cells has, according to Dr. Robin Smith, stifled the advances made in adult stem cells, which are derived from adult tissue samples. Dr. Smith serves as president of the Stem for Life Foundation as well as CEO of NeoStem, a leading developer in cellular therapy.

Stem Cell Therapy, especially using cultivated adult stem cells , can be used to regenerate dying tissue in the body of a person suffering debilitating diseases, such as Alzheimers, Parkinsons, or Multiple Sclerosis (MS).

In November 2001, we kicked of the first Stem Cell Conference. Since then, the entire world has awakened.

By improving the clinical outcomes, we can save hundreds of millions of lives, she said. We're not talking about medications, she continued. Were talking about repairing the heart with adult stem cells. Re-inserting these cells into a damaged organ is turning back the clock. In just 17 months, we have seen stunning advancements in leukemia treatments.

The work in stem cell research has only begun to be understood. The last conference did not have panels that discussed the benefits of cellular therapy on MS and diabetes. Dr. Smith stated that in the United States, $245 billion is spent on managing diabetes, which can cause blindness, stroke and amputations which is only getting worse.

Cellular therapy has the potential to rewrite the history of this disease, she said. Adult stem cells is something we can all agree upon; they are ethically pure. We can grasp whats inside of us and introduce them into the body.

The purpose of the conference, she concluded, was meant to inspire change and to promote the truth and promise behind stem cell science. We hope to show that you no longer have to choose between science and faith.

In Search of Hope

See the original post:
Vatican Conference Hopes to Promote Truth on Adult Stem Cell Therapy

Read More...

Stem Cell Therapy – Blue Horizon Stem Cells – Video

April 11th, 2013 9:41 am


Stem Cell Therapy - Blue Horizon Stem Cells

By: Michael McDermott

See more here:
Stem Cell Therapy - Blue Horizon Stem Cells - Video

Read More...

Stem Cell Therapy Treatment for Limb Girdle Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. – Video

April 10th, 2013 7:43 pm


Stem Cell Therapy Treatment for Limb Girdle Muscular Dystrophy by Dr Alok Sharma, Mumbai, India.
Stem Cell Therapy Treatment for Limb Girdle Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy 1. Power and movements in the finger...

By: neurogenbsi

See the original post here:
Stem Cell Therapy Treatment for Limb Girdle Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. - Video

Read More...

Stem Cell Therapy Treatment for Polymyositis by Dr Alok Sharma, Mumbai, India. – Video

April 10th, 2013 7:43 pm


Stem Cell Therapy Treatment for Polymyositis by Dr Alok Sharma, Mumbai, India.
Stem Cell Therapy Treatment for Polymyositis by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy 1) Patient had a fall on 31st December 2012 due to whi...

By: neurogenbsi

See the rest here:
Stem Cell Therapy Treatment for Polymyositis by Dr Alok Sharma, Mumbai, India. - Video

Read More...

Stem Cell Therapy Treatment for Inclusive Body Myopathy by Dr Alok Sharma, Mumbai, India. Part 2 – Video

April 10th, 2013 7:43 pm


Stem Cell Therapy Treatment for Inclusive Body Myopathy by Dr Alok Sharma, Mumbai, India. Part 2

By: neurogenbsi

See more here:
Stem Cell Therapy Treatment for Inclusive Body Myopathy by Dr Alok Sharma, Mumbai, India. Part 2 - Video

Read More...

Performance After Adipose Stem Cell Therapy for Horse – Cash Fuez and Flaxey – Video

April 9th, 2013 11:43 am


Performance After Adipose Stem Cell Therapy for Horse - Cash Fuez and Flaxey
Performance After Adipose Stem Cell Therapy for Horse - Cash Fuez and Flaxey http://wichitaequinevet.com "This is the video of Flaxey after he and Cash won t...

By: WichitaEquine

Excerpt from:
Performance After Adipose Stem Cell Therapy for Horse - Cash Fuez and Flaxey - Video

Read More...

A Century of Stem Cells – Johns Hopkins Medicine – Video

April 8th, 2013 3:46 pm


A Century of Stem Cells - Johns Hopkins Medicine

By: adamkps

Read the original:
A Century of Stem Cells - Johns Hopkins Medicine - Video

Read More...

Page 1,314«..1020..1,3131,3141,3151,316..1,3201,330..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick